胰腺神经内分泌肿瘤的淋巴结转移与复发
该回顾性队列研究分析了2001至2019年间605例接受胰腺切除的胰腺神经内分泌肿瘤患者,其中34%存在淋巴结转移。在314例散发、无功能、无远处转移且检查淋巴结≥4枚的亚组中,淋巴结转移率为36%,且淋巴结转移数目与无病生存显著相关,研究首次验证了提出的pN2分期。
要点
- 胰腺神经内分泌肿瘤患者中淋巴结转移常见,总体发生率为34%。
- 淋巴结转移是复发的独立预测因素,且转移数目越多预后越差。
- 研究验证了pN2分期对高分化胰腺神经内分泌肿瘤的预后价值。
核心结论
- 淋巴结转移的存在和范围对胰腺神经内分泌肿瘤具有重要预后影响,并首次验证了提出的pN2分期。
研究设计与样本
- 基于前瞻性数据库的回顾性分析,纳入2001至2019年接受胰腺切除的胰腺神经内分泌肿瘤患者605例,亚组分析纳入314例散发、无功能、无远处转移且检查淋巴结≥4枚的患者。
主要发现
- 605例患者中55%为G1、36%为G2、9%为G3分化;切除时34%有淋巴结转移,16%有远处转移。
- 亚组分析中淋巴结转移发生率为36%,G3患者最高为67%;肿瘤增大和分期进展与淋巴结转移率升高相关。
- 1-3枚阳性淋巴结患者5年无病生存率为52%,≥4枚阳性淋巴结患者为28%,排除G3肿瘤后差异仍显著。
- 多因素分析证实分级、肿瘤分期、淋巴结转移及提出的pN1和pN2分类是复发的独立预测因素。
关键数值与推荐
- 1-3枚阳性淋巴结:5年无病生存率52%;≥4枚阳性淋巴结:5年无病生存率28%。
- 亚组中G3患者淋巴结转移率67%,总体淋巴结转移率36%。
临床怎么用
- 对胰腺神经内分泌肿瘤患者应重视淋巴结评估,阳性淋巴结数目有助于风险分层和预后判断。
- pN2分期可用于高分化胰腺神经内分泌肿瘤的复发风险预测。
局限性
- 回顾性研究设计。
- 亚组分析仅纳入检查淋巴结≥4枚的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of lymph node metastasis on survival in pancreatic neuroendocrine neoplasms as well as their best surgical treatment is controversial. We aimed to determine the frequency and prognostic impact of lymph node involvement in pancreatic neuroendocrine neoplasms. METHODS: Patients undergoing pancreatic resections for pancreatic neuroendocrine neoplasms between 2001 and 2019 were retrospectively analyzed based on a prospective database. Clinicopathological parameters and perioperative outcome were assessed. Overall and disease-free survival was analyzed. Subgroup analysis was performed for sporadic, nonfunctional pancreatic neuroendocrine neoplasms without distant metastases and ≥4 analyzed lymph nodes. RESULTS: Of 605 surgically resected pancreatic neuroendocrine neoplasms, 55% were G1, 36% were G2, and 9% were G3 differentiated. At the time of resection, 34% of patients had lymph node metastasis, and 16% had distant metastases. For subgroup analysis, 314 patients were analyzed. Lymph node metastases occurred in 36% of patients and were most frequent in G3 patients (67%). An increase in tumor size and advancement was associated with higher rates of lymph node metastasis, and disease-free survival was significantly impaired. Significant differences in disease-free survival were observed between 1 and 3 (5-year disease-free survival 52%) and ≥4 positive lymph nodes (5-year disease-free survival 28%), as well as when G3 tumors were excluded. In multivariable analysis, grading, tumor stage, and especially lymph node metastases as well as the proposed pN1 and pN2 categories were confirmed as independent predictors of recurrence. CONCLUSION: The presence and extent of lymph node involvement has considerable prognostic impact in pancreatic neuroendocrine neoplasms. This study, for the first time, validated the proposed pN2 stage for well-differentiated pancreatic neuroendocrine neoplasms.
引用
- Nießen A, Schimmack S, Lewosinska M, et al. Lymph node metastases and recurrence in pancreatic neuroendocrine neoplasms. Surgery. 2022. PMID: 36180252. doi:10.1016/j.surg.2022.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。